The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://loriwoim490253.oneworldwiki.com/7328286/glp_3_retatrutide_a_comparative_analysis